Nanoconjugates able to cross the blood-brain barrier
AssigneeNorthwestern University
InventorsChad A. Mirkin, Caroline H. Ko, Alexander Stegh, David A. Giljohann, Janina Luciano, Samuel A. Jensen
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to nanoconjugates that cross the blood-brain barrier and methods of their therapeutic use.
Claims15
1-11. (canceled)
A method of treating a patient in need of a composition that is able to traverse the blood-brain barrier, comprising administering to the patient a therapeutically effective amount of a composition comprising a functionalized nanoconjugate, the nanoconjugate comprising a polynucleotide having a sequence sufficiently complementary to a target polynucleotide to hybridize to and inhibit expression of the target polynucleotide.
A method of administering a composition comprising a functionalized nanoconjugate to a patient, the method comprising administering to the patient a therapeutically effective amount of the composition;
- wherein the nanoconjugate comprises a polynucleotide having a sequence sufficiently complementary to a target polynucleotide to hybridize to and inhibit expression of the target polynucleotide, said composition having the ability to traverse the blood-brain barrier, and wherein the patient is in need of a composition that is able to traverse the blood-brain barrier.
Dependencies are inferred from the claim text.